Bavarian Nordic
Update in progressBAVA.CO (Copenhagen)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Bavarian Nordic A/S develops, manufactures, and supplies vaccines. It offers non-replicating smallpox and monkeypox vaccines (IMVAMUNE/IMVANEX/JYNNEOS), rabies vaccines (Rabipur/RabAvert), a tick-borne encephalitis vaccine (Encepur), the oral cholera vaccine Vaxchora, and the oral typhoid vaccine Vivotif/Typhoral. It is advancing MVA-BN WEV for encephalitis viruses (phase 2). Headquartered in Hellerup, Denmark, it operates globally.
Company score
- Sentiment
- 1.16
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.07
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 1.41
- Governance
- 0.47
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.54
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.85
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketCopenhagen (CPH)
- LocationDenmark
- CEODr. Paul John Chaplin MSc, Ph.D.
- Founded1992
- Employees1,906
- Websitewww.bavarian-nordic.com
Identifiers
- ISINDK0015998017
- LEI2138006JCDVYIN6INP51